Lytix Biopharma AS announced that data from the ATLAS-IT-04 study has been published a paper entitled ?LTX-315 and adoptive cell therapy using tumor-infiltrating lymphocytes generate tumor specific T cells in patients with metastatic soft tissue sarcoma?. The paper is published in OncoImmunology, a high-profile, open access journal covering tumor immunology and immunotherapy. The ATLAS-IT-04 trial was an open label, Phase II trial assessing the effect of LTX-315 when used in combination with Adoptive Cell Therapy (ACT) in patients with progressive metastatic soft tissue sarcoma that had failed standard of care of treatment.

The ATLAS-IT-04 trial included intra-tumoral injections of LTX-315 ahead of surgical removal of tumors, followed by in vitro expansion of T cells isolated from the resected tumor. In a second step, the expanded T cells were infused back to the patients. Six heavily pretreated patients were included in the trial and treated with LTX-315, of which four patients proceeded to adoptive T-cell therapy.

The treatment was safe, and the best overall clinical response was stabilization of the disease for 208 days. The immune response data from the trial demonstrated that the treatment induces tumor specific T cells in blood, providing proof of concept that LTX-315 generates an immune response that targets the tumor.